Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center.

• Age \> 18 years

Locations
Other Locations
Israel
Shamir Medical Center
RECRUITING
Be’er Ya‘aqov
Contact Information
Primary
Anton Bermont, MD
bermont@doctor.com
+972526944145
Backup
Sergei Vosko, MD
sergeivosko@gmail.com
Time Frame
Start Date: 2022-05-01
Estimated Completion Date: 2025-10-01
Participants
Target number of participants: 200
Treatments
Experimental: Tranexamic Acid group
standard solution for injection with TXA and without adrenaline
Placebo_comparator: Standard therapy group
standard solution for injection including adrenaline
Related Therapeutic Areas
Sponsors
Leads: Assaf-Harofeh Medical Center

This content was sourced from clinicaltrials.gov